EXPLORE CONNECTIONS
Integrated molecular and immune profiling identifies FOXA1 as a complementary co-target to MUC1 for bispecific immunotherapy in breast cancer.
Follow the relationships that help you find your next source.
Connections are not prepared for this record yet, or its source metadata has changed. The original record remains available while background snapshots are rebuilt.